Indiana University School of Medicine is partnering with the Northwest Indiana GME Consortium to launch a new psychiatry residency program at its regional campus in northwest Indiana aimed at treating an underserved population in that part of the state.
Researchers at Indiana University School of Medicine are hoping to develop a new model to help those who experience a traumatic brain injury (TBI) recover and better manage challenges that result from their injury.
The Walther Cancer Foundation will invest $11 million to advance collaborative cancer research at Indiana University and Purdue University by supporting scientists through bioinformatics — an increasingly critical aspect of their work.
Indiana University School of Medicine has announced the hiring of a world-recognized medical oncologist and multiple myeloma researcher to lead the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, bolstered by a $15 million fund established by the Walther Cancer Foundation to support him in this role.
Indiana University School of Medicine researchers are participating in the Rare and Atypical Diabetes Network (RADIANT), a nationwide study funded by the National Institutes of Health. The study seeks to discover new forms of diabetes, identify their causes, and understand how they differ from more common types of diabetes.
Researchers at Indiana University School of Medicine are testing use of tezampanel, a novel antagonist at glutamate receptors that could treat opioid withdrawal syndrome and other addictions and mental illnesses.
Supported by a $1.3 million grant from the U.S. Administration for Community Living, Department of Health and Human Services, Indiana University School of Medicine and its partners have launched a 36-month venture to enhance, strengthen and expand supports for people with Alzheimer’s Disease and Related Dementias and their caregivers in 34 Indiana counties.
As researchers around the world work feverishly to discover a vaccine in the battle to prevent COVID-19, Indiana University School of Medicine has been selected as a site for a vaccine trial. Biopharmaceutical company AstraZeneca, in partnership with Oxford University, is moving forward with its late-stage clinical trial for a vaccine known as AZD1222.